Cover Image
市場調查報告書

乳癌治療藥市場:產業分析,各地區的預測,技術開發,競爭情形,預測

Breast Cancer Therapeutics Market Size By Product (Hormone Drugs, Chemotherapy Drugs, Targeted Drug Therapy), Distribution Channel, Regional Outlook, Technology Development, Competitive Landscape & Forecast, 2017 - 2024

出版商 Global Market Insights Inc. 商品編碼 575357
出版日期 內容資訊 英文 120 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
乳癌治療藥市場:產業分析,各地區的預測,技術開發,競爭情形,預測 Breast Cancer Therapeutics Market Size By Product (Hormone Drugs, Chemotherapy Drugs, Targeted Drug Therapy), Distribution Channel, Regional Outlook, Technology Development, Competitive Landscape & Forecast, 2017 - 2024
出版日期: 2017年09月27日 內容資訊: 英文 120 Pages
簡介

本報告提供全球乳癌治療藥市場相關調查分析,產業的考察,各市場區隔的市場分析,各地區的分析,主要企業等系統性資訊。

第1章 調查手法

第2章 摘要整理

第3章 乳癌治療藥市場:產業的考察

  • 產業區分
  • 產業形勢
  • 產業影響力
  • 流行病學形勢
  • 成長潛在力分析
  • 開發平台分析
  • 波特的五力分析
  • 企業的市場佔有率分析
  • PESTEL分析

第4章 乳癌治療藥市場:各產品

  • 市場佔有率
  • 荷爾蒙劑
  • 化療藥
  • 標靶藥物治療

第5章 乳癌治療藥市場:各銷售管道

  • 市場佔有率
  • 醫院
  • ASC
  • 診所
  • 電子商務
  • 零售藥局

第6章 乳癌治療藥市場:各地區

  • 市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第7章 企業簡介

  • AstraZeneca
  • Eisai
  • Eli Lilly
  • Roche Diagnostics
  • Novartis AG
  • Pfizer
  • Celgene
  • Sanofi
  • Teva Pharmaceutical
目錄
Product Code: 466

Title:
Breast Cancer Therapeutics Market
Size By Product (Hormone Drugs, Chemotherapy Drugs, Targeted Drug Therapy), By Distribution Channel (Hospitals, Ambulatory Surgical Centers, Clinics, e-commerce, Retail Pharmacies), Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Spain, Russia, Poland, China, India, Japan, India, Australia, Malaysia, Indonesia, Thailand, Brazil, Mexico, Argentina, South Africa, UAE, Qatar, Saudi Arabia, Kuwait, Egypt), Technology Development, Competitive Landscape & Forecast, 2017 - 2024.

Breast Cancer Therapeutics Market size is set to exceed USD 28 billion by 2024; according to a new research report by Global Market Insights, Inc.

Increasing prevalence of breast cancer, introduction of various diagnostic and screening programs across the world and favorable reimbursement policies should drive breast cancer therapeutics market growth over the forecast period.

Advancement in cancer biology technologies, growing investment in research and development activities for novel drugs used in the treatment of disease should drive industry growth over the forecast timeframe. Growing adoption of minimally invasive cancer therapy should further drive breast cancer therapeutics market size.

Furthermore, rising awareness levels regarding disease prevention, early diagnosis and screening should drive the industry revenue. However, high cost associated with breast cancer therapeutics, stringent regulatory guidelines, complications associated with chemotherapy and patent expiry of drugs can restrain industry growth.

Targeted drug therapy should contribute for significant revenue share in 2016. Targeted drugs block the growth of cancerous cells. It targets abnormal protein HER2 (human epidermal growth factor) to stimulate growth of breast cancer cells. Increased focus on anticancer drug development for targeted therapies should drive the demand for these products.

Hormone drugs should witness substantial growth over the forecast period. Growth is attributed due to its use to stop or slow down the hormonal sensitive tumor growth. Hormonal drugs function to interfere with body's hormone production ability or by obstructing effects of hormones such as progesterone and estrogen on breast cancer cells. Furthermore, growing incidence rate of breast cancer, increasing acceptance of hormonal therapy to curb disease occurrence and growing usage of therapy as adjuvant therapy should drive hormonal drugs market growth over the forecast period.

Distribution of breast cancer therapeutics through retail pharmacies contributed for major revenue share in 2016. Rising number of pharmacies in both developed and developing regions should drive industry growth over the forecast period. Large number of retail pharmacies and their software systems have facility of screening harmful drug interactions which will further drive segment growth.

U.S. breast cancer therapeutics market size held major revenue share in 2016, and it is expected to grow at substantial rate over the forecast timeframe. Presence of well-established healthcare infrastructure and growing healthcare expenditure should drive industry growth. Increased access to breast cancer screening and growing adoption of therapy drugs among patients should further drive business growth in the U.S.

Germany should experience significant growth over the forecast period. Rising prevalence of disease and arrangements of various symposiums and conferences to spread awareness regarding the disease in the country are the factors driving industry growth over the forecast period.

Japan should contribute for considerable growth over the forecast period. Increasing mortality rates related to breast cancer have raised serious concerns in the country. Moreover, robust healthcare insurance system and well-developed infrastructure will drive business growth in the region.

South Africa is expected to grow at a lucrative rate over the forecast timeframe. Various organizations taking significant efforts to increase the awareness and accessibility will drive the business over the forecast period.

Some of the companies operating in breast cancer therapeutics market includes Novartis, Roche Diagnostics, Pfizer, Eisai, AstraZeneca, Eli Lily, and Sanofi. Strategies implemented by the companies includes geographical expansion, launch of new products, strong product pipeline, mergers, and acquisition to enhance their business.

Table of Contents

Chapter 1. Methodology

  • 1.1. Methodology
    • 1.1.1. Initial data exploration
    • 1.1.2. Statistical modeling and forecast
    • 1.1.3. Industry insights and validation
    • 1.1.4. Market definition and forecast assumptions
  • 1.2. Data Sources
    • 1.2.1. Primary
    • 1.2.2. Secondary

Chapter 2. Executive Summary

  • 2.1. Breast cancer therapeutics industry 360 degree synopsis, 2013 - 2024
    • 2.1.1. Business trends
    • 2.1.2. Product trends
    • 2.1.3. Distribution channel trends
    • 2.1.4. Regional trends

Chapter 3. Breast Cancer Therapeutics Industry Insights

  • 3.1. Industry segmentation
  • 3.2. Industry landscape, 2013 - 2024
  • 3.3. Industry impact forces
    • 3.3.1. Growth drivers
      • 3.3.1.1. Increasing breast cancer prevalence in the developed countries
      • 3.3.1.2. Advancements in cancer biology
      • 3.3.1.3. Launch of several diagnostic and screening programs worldwide
      • 3.3.1.4. Favorable insurance and reimbursement policies
    • 3.3.2. Industry pitfalls & challenges
      • 3.3.2.1. High cost of breast cancer therapeutics
  • 3.4. Epidemiology landscape
    • 3.4.1. U.S
    • 3.4.2. Europe
  • 3.5. Growth potential analysis
    • 3.5.1. By Product
    • 3.5.2. By Distribution channel
  • 3.6. Pipeline analysis
  • 3.7. Porter's analysis
  • 3.8. Company market share analysis, 2016
    • 3.8.1. Strategy dashboard
  • 3.9. PESTEL analysis

Chapter 4. Breast Cancer Therapeutics Market, By Product

  • 4.1. Global breast cancer therapeutics market share by product, 2016 & 2024
  • 4.2. Hormone Drugs
    • 4.2.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)
  • 4.3. Chemotherapy Drugs
    • 4.3.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)
  • 4.4. Targeted Drug Therapy
    • 4.4.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

Chapter 5. Breast Cancer Therapeutics Market, By Distribution Channel

  • 5.1. Global breast cancer therapeutics market share by distribution channel, 2016 & 2024
  • 5.2. Hospitals
    • 5.2.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)
  • 5.3. Ambulatory surgical centers
    • 5.3.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)
  • 5.4. Clinics
    • 5.4.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)
  • 5.5. e-commerce
    • 5.5.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)
  • 5.6. Retail pharmacies
    • 5.6.1. Market estimates and forecast, by region, 2013 - 2024 (USD Million)

Chapter 6. Breast Cancer Therapeutics Market, By Region

  • 6.1. Breast cancer therapeutics market share by region, 2016 & 2024
  • 6.2. North America
    • 6.2.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
    • 6.2.2. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
    • 6.2.3. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.2.4. U.S.
      • 6.2.4.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.2.4.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.2.5. Canada
      • 6.2.5.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.2.5.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
  • 6.3. Europe
    • 6.3.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
    • 6.3.2. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
    • 6.3.3. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.3.4. Germany
      • 6.3.4.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.3.4.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.3.5. UK
      • 6.3.5.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.3.5.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.3.6. France
      • 6.3.6.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.3.6.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.3.7. Italy
      • 6.3.7.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.3.7.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.3.8. Spain
      • 6.3.8.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.3.8.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.3.9. Russia
      • 6.3.9.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.3.9.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.3.10. Poland
      • 6.3.10.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.3.10.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
    • 6.4.2. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
    • 6.4.3. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.4.4. China
      • 6.4.4.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.4.4.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.4.5. India
      • 6.4.5.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.4.5.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.4.6. Japan
      • 6.4.6.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.4.6.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.4.7. Australia
      • 6.4.7.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.4.7.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.4.8. Malaysia
      • 6.4.8.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.4.8.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.4.9. Indonesia
      • 6.4.9.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.4.9.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.4.10. Thailand
      • 6.4.10.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.4.10.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
    • 6.5.2. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
    • 6.5.3. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.5.4. Brazil
      • 6.5.4.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.5.4.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.5.5. Mexico
      • 6.5.5.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.5.5.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.5.6. Argentina
      • 6.5.6.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.5.6.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
  • 6.6. Middle East & Africa
    • 6.6.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)
    • 6.6.2. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
    • 6.6.3. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.6.4. South Africa
      • 6.6.4.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.6.4.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.6.5. UAE
      • 6.6.5.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.6.5.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.6.6. Qatar
      • 6.6.6.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.6.6.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.6.7. Saudi Arabia
      • 6.6.7.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.6.7.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.6.8. Kuwait
      • 6.6.8.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.6.8.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)
    • 6.6.9. Egypt
      • 6.6.9.1. Market estimates and forecast, by product, 2013 - 2024 (USD Million)
      • 6.6.9.2. Market estimates and forecast, by distribution channel, 2013 - 2024 (USD Million)

Chapter 7. Company Profiles

  • 7.1. AstraZeneca
    • 7.1.1. Business overview
    • 7.1.2. Financial data
    • 7.1.3. Product landscape
    • 7.1.4. Strategic outlook
    • 7.1.5. SWOT analysis
  • 7.2. Eisai Co., Ltd.
    • 7.2.1. Business overview
    • 7.2.2. Financial data
    • 7.2.3. Product landscape
    • 7.2.4. Strategic outlook
    • 7.2.5. SWOT analysis
  • 7.3. Eli Lilly
    • 7.3.1. Business overview
    • 7.3.2. Financial data
    • 7.3.3. Product landscape
    • 7.3.4. Strategic outlook
    • 7.3.5. SWOT analysis
  • 7.4. Roche Diagnostics
    • 7.4.1. Business overview
    • 7.4.2. Financial data
    • 7.4.3. Product landscape
    • 7.4.4. Strategic outlook
    • 7.4.5. SWOT analysis
  • 7.5. Novartis AG
    • 7.5.1. Business overview
    • 7.5.2. Financial data
    • 7.5.3. Product landscape
    • 7.5.4. Strategic outlook
    • 7.5.5. SWOT analysis
  • 7.6. Pfizer
    • 7.6.1. Business overview
    • 7.6.2. Financial data
    • 7.6.3. Product landscape
    • 7.6.4. Strategic outlook
    • 7.6.5. SWOT analysis
  • 7.7. Celgene
    • 7.7.1. Business overview
    • 7.7.2. Financial data
    • 7.7.3. Product landscape
    • 7.7.4. Strategic outlook
    • 7.7.5. SWOT analysis
  • 7.8. Sanofi
    • 7.8.1. Business overview
    • 7.8.2. Financial data
    • 7.8.3. Product landscape
    • 7.8.4. Strategic outlook
    • 7.8.5. SWOT analysis
  • 7.9. Teva Pharmaceutical
    • 7.9.1. Business overview
    • 7.9.2. Financial data
    • 7.9.3. Product landscape
    • 7.9.4. Strategic outlook
    • 7.9.5. SWOT analysis

Data Tables

  • TABLE 1. Breast cancer therapeutics industry 360 degree synopsis, 2013 - 2024
  • TABLE 2. Global breast cancer therapeutics market, 2013-2014 (USD Million)
  • TABLE 3. Global breast cancer therapeutics market, by product, 2013-2024 (USD Million)
  • TABLE 4. Global breast cancer therapeutics market, by distribution channel, 2013-2024 (USD Million)
  • TABLE 5. Global breast cancer therapeutics market, by region, 2013-2024 (USD Million)
  • TABLE 6. Industry impact forces
  • TABLE 7. Breast cancer therapeutics pipeline overview
  • TABLE 8. Hormone drugs market, by region, 2013 - 2024, (USD Million)
  • TABLE 9. Chemotherapy drugs market, by region, 2013 - 2024, (USD Million)
  • TABLE 10. Targeted drug therapy market, by region, 2013 - 2024, (USD Million)
  • TABLE 11. Hospitals market, by region, 2013 - 2024, (USD Million)
  • TABLE 12. Ambulatory surgical centres market, by region, 2013 - 2024, (USD Million)
  • TABLE 13. Clinics market, by region, 2013 - 2024, (USD Million)
  • TABLE 14. e-commerce market, by region, 2013 - 2024, (USD Million)
  • TABLE 15. Retail pharmacies market, by region, 2013 - 2024, (USD Million)
  • TABLE 16. North America breast cancer therapeutics market, by country 2013 - 2024 (USD Million)
  • TABLE 17. North America breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 18. North America breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 19. U.S. breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 20. U.S. breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 21. Canada breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 22. Canada breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 23. Europe breast cancer therapeutics market, by country 2013 - 2024 (USD Million)
  • TABLE 24. Europe breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 25. Europe breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 26. Germany breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 27. Germany breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 28. UK breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 29. UK breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 30. France breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 31. France breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 32. Spain breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 33. Spain breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 34. Italy breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 35. Italy breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 36. Russia breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 37. Russia breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 38. Poland breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 39. Poland breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 40. Asia Pacific Breast Cancer Therapeutics market, by country 2013 - 2024 (USD Million)
  • TABLE 41. Asia Pacific breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 42. Asia Pacific breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 43. Japan breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 44. Japan breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 45. China breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 46. China breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 47. India breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 48. India breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 49. Australia breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 50. Australia breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 51. Malaysia breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 52. Malaysia breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 53. Indonesia breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 54. Indonesia breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 55. Thailand breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 56. Thailand breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 57. Latin America Breast Cancer Therapeutics market, by country 2013 - 2024 (USD Million)
  • TABLE 58. Latin America breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 59. Latin America breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 60. Mexico breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 61. Mexico breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 62. Brazil breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 63. Brazil breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 64. Argentina breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 65. Argentina breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 66. MEA breast cancer therapeutics market, by country 2013 - 2024 (USD Million)
  • TABLE 67. MEA breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 68. MEA breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 69. South Africa breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 70. South Africa breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 71. UAE breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 72. UAE breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 73. Qatar breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 74. Qatar breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 75. Saudi Arabia breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 76. Saudi Arabia breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 77. Kuwait breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 78. Kuwait breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)
  • TABLE 79. Egypt breast cancer therapeutics market, by product, 2013 - 2024 (USD Million)
  • TABLE 80. Egypt breast cancer therapeutics market, by distribution channel, 2013 - 2024 (USD Million)

Charts & Figures

  • FIG. 1. Industry segmentation
  • FIG. 2. Global breast cancer therapeutics market, 2013- 2024 (USD Million)
  • FIG. 3. Age adjusted female breast cancer incidence rates, U.S., 2004 & 2014
  • FIG. 4. Growth potential analysis, by product
  • FIG. 5. Growth potential analysis, by distribution channel
  • FIG. 6. Porter's analysis
  • FIG. 7. Company share analysis, 2016
  • FIG. 8. Strategic dashboard, 2016
  • FIG. 9. PESTEL analysis
  • FIG. 10. Breast cancer therapeutics market share by product, 2016 & 2024
  • FIG. 11. Breast cancer therapeutics market share by distribution channel, 2016 & 2024
  • FIG. 12. Breast cancer therapeutics market share, by region, 2016 & 2024
Back to Top